Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION April Drug Price Revision “Will Be a Hard One” for the Industry: Pharma Leader Nakayama
January 7, 2016
-
TRENDS Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
-
ACADEMIA Shionogi Funding Research to Develop World’s First Drug for Preventing Postoperative Metastasis of Lung Cancer
January 5, 2016
-
ORGANIZATION FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
-
REGULATORY Chuikyo OKs Outline of FY2016 Drug Pricing Reform
December 25, 2015
-
REGULATORY Plavix, 15 Other Brands to Lose Premiums on Generic, Biosimilar Entries; Re-Pricing Could Deal Another Blow
December 24, 2015
-
REGULATORY Drug Prices to Be Pared 7.8% If Re-Pricing, Z2, Generic Price Cuts Included
December 22, 2015
-
REGULATORY Govt to Shed 28 Bil. Yen via Huge Seller Drugs, 20 Bil. Yen via Existing Re-Pricing Rule; Physicians to Win “Plus” Revision
December 21, 2015
-
REGULATORY ICH Reaches Agreement to Treat Subjects with Similar Ethnic Factors as Single Populations Regardless of Nationality
December 18, 2015
-
REGULATORY Survey Finds Unexpectedly Low Market Prices for Injectable Generics; Industry to Accept 50% Rule
December 17, 2015
-
REGULATORY Chuikyo Subcommittee OKs Outline of FY2016 Drug Pricing Reform, Rollout of “Huge Seller” Re-Pricing
December 17, 2015
-
BUSINESS LEO Pharma “Eager to Do More” after Astellas Deal to Expand Globally: CEO
December 16, 2015
-
BUSINESS Mundipharma Poised to Expand Japan Operations by Tapping Isodine Brand: Asia Head
December 15, 2015
-
ORGANIZATION PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
-
REGULATORY 6 Drug Makers to Participate in AMED’s Drug Discovery Consortium
December 11, 2015
-
REGULATORY 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
-
TRENDS “Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
-
REGULATORY LDP Budget Debate in Homestretch; Govt Eyes “Huge Sellers”, Generics, Z2 to Squeak Out Funds for Upping Physician Fees
December 9, 2015
-
REGULATORY PMDA to Begin Unannounced Regular Inspections in Wake of GMP Violations by Kaketsuken
December 8, 2015
-
TRENDS Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…